Skip to main content

Table 1 Characteristics of the Lifelines participants (N = 162,416)

From: Familial co-aggregation and shared genetics of cardiometabolic disorders and traits: data from the multi-generational Lifelines Cohort Study

Baseline characteristic

All participants (N = 162,416)

Adults (N = 152,723)

Children (N = 9693)

N

n/mean ± SD/median (IQR)

Prevalence (%)

N

n/mean ± SD/median (IQR)

Prevalence (%)

N

n/mean ± SD/median (IQR)

Prevalence (%)

Age (years)

162,416

42.68 ± 14.92

 

152,723

44.63 ± 13.13

 

9693

11.97 ± 2.77

 

Gender (female)

162,416

94,428

58.1

152,723

89,340

58.5

9693

5088

52.5

Any cardiometabolic disorder

   

152,723

66,695

43.7

N/A

Single disease

   

152,723

35,075

23

N/A

Multi-morbidities (>1 diseases)

   

152,723

31,620

20.7

N/A

Cardiometabolic disorders

One or more cardiovascular diseases

   

152,230

4526

3

N/A

 MI with drug use or ECG abnormalities

   

152,230

1881

1.2

N/A

 Self-reported heart failure with drug use or therapy

   

152,230

802

0.5

N/A

 Self-reported cardiac surgery (PTCA, CABG, and stent positioning)

   

152,230

2221

1.5

N/A

 Self-reported stroke

   

152,230

1178

0.8

N/A

Type 2 diabetes

   

152,341

4844

3.2

N/A

Hypertension

   

151,342

39,645

26.2

N/A

Obesity

   

152,588

23,861

15.6

N/A

Hypercholesterolemia

   

147,785

23,012

15.6

N/A

Metabolic syndrome

   

144,400

27,847

19.3

N/A

Cardiometabolic traits

Waist circumference (cm)

162,278

88.80 ± 13.48

 

152,588

90.16 ± 12.51

 

9690

67.30 ± 9.32

 

Body weight (Kg)

162,279

77.86 ± 17.11

 

152,588

79.77 ± 15.33

 

9691

47.70 ± 15.23

 

Body height (cm)

162,281

173.75 ± 10.72

 

152,590

174.79 ± 9.43

 

9691

157.50 ± 15.65

 

BMI (Kg/m2)

162,279

25.62 ± 4.63

 

152,588

26.06 ± 4.35

 

9691

18.72 ± 3.19

 

Systolic Blood Pressure* (mmHg)

162,306

126.04 ± 17.53

 

152,628

127.29 ± 17.13

 

9678

106.43 ± 10.82

 

Diastolic Blood Pressure* (mmHg)

162,306

73.96 ± 10.77

 

152,628

74.88 ± 10.33

 

9678

59.51 ± 6.28

 

Skin auto fluorescence (z-score)

83,057

1.93 ± 0.44

 

83,057

1.93 ± 0.44

 

N/A

C-reactive protein (mg/l)

49,924

1.2 (0.00–247.00)

 

49,487

1.2 (0.0–247.0)

 

437

0.5 (0.20–69.50)

 

Leukocyte count (109/l)

155,477

5.8 (1.20–126.60)

 

147,353

5.8 (1.2–126.6)

 

8124

5.5 (1.60–17.40)

 

Total cholesterol*(mmol/l)

155,855

6.27 ± 1.27

 

147,658

6.33 ± 1.26

 

8197

5.10 ± 0.85

 

Triglycerides (mmol/l)

155,855

0.96 (0.01–37.31)

 

147,658

0.98 (0.01–37.31)

 

8197

0.65 (0.11–8.11)

 

HDL cholesterol (mmol/l)

155,854

1.49 ± 0.39

 

147,657

1.49 ± 0.40

 

8197

1.55 ± 0.33

 

LDL cholesterol* (mmol/l)

155,845

4.43 (0.17–18.86)

 

147,648

4.57 (0.14–18.86)

 

8197

3.29 (0.14–10.29)

 

Apolipoprotein A (mmol/l)

42,103

1.54 ± 0.27

 

41,751

1.54 ± 0.27

 

352

1.40 ± 0.20

 

Apolipoprotein B (mmol/l)

42,090

0.92 ± 0.24

 

41,738

0.93 ± 0.24

 

352

0.64 ± 0.16

 

HbA1c (%)

154,818

5.50 (2.50–16.40)

 

146,755

5.50 (2.50–16.40)

 

8063

5.40 (2.80–15.00)

 

Fasting blood glucose (mmol/l)

151,530

4.90 (1.90–24.40)

 

143,640

4.90 (1.90–24.40)

 

7890

4.60 (2.00–18.30)

 
  1. CABG: coronary artery bypass graft; MI: myocardial infarction; N/A: not available; PTCA: percutaneous transluminal coronary angioplasty
  2. *Values are adjusted for anti-hypertensive or lipid-lowering medication. For systolic blood pressure 15 mmHg was added and for diastolic blood pressure 10 mmHg was added in individuals taking anti-hypertensive medication, while total cholesterol was divided by 0.8 and LDL cholesterol were divided by 0.7 in individuals taking lipid lowering medication
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840